The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-market entrants of existing drug classes or combination treatments. Notable market growth is expected from the sodium glucose cotransporter-2 (SGLT-2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists due to their efficacy in glycemic control and weight loss and demonstration of cardiovascular (CV) benefits, although they will face reimbursement hurdles and an increasingly stringent regulatory environment. Consequently, a high unmet need exists for affordable drugs that can safely and effectively control T2D in the long term.
- How do endocrinologists rate current T2D drug classes such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists as well as long-acting, short-acting, and rapid-acting insulins?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What trade-offs across different clinical attributes and prices are needed from new antidiabetic drugs in order to be preferred by endocrinologists?
- Is an injectable drug with CV benefits preferable to an oral drug offering stronger glycemic control? Discover the answer with DRG’s fully customizable Target Product Profile (TPP) simulator.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 30 European endocrinologists fielded in August 2019.
Key companies: Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma, Boehringer Ingelheim.
Key drug classes: DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists (once daily), GLP-1 receptor agonists (once weekly), long-acting insulins, short-acting insulins, rapid-acting insulins.
- Type 2 Diabetes - Unmet Need - Detailed, Expanded Analysis: Injectables (US/EU)
Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.)
Rameshwar Prajapati, Ph.D., M.S. (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications.
Rameshwar holds a bachelor’s degree in pharmacy from Dr. H.S. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, S.A.S Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.